BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 7539339)

  • 41. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma.
    Westermann AM; Wiedemann GJ; Jager E; Jager D; Katschinski DM; Knuth A; Vörde Sive Vörding PZ; Van Dijk JD; Finet J; Neumann A; Longo W; Bakhshandeh A; Tiggelaar CL; Gillis W; Bailey H; Peters SO; Robins HI;
    Oncology; 2003; 64(4):312-21. PubMed ID: 12759526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.
    Harstrick A; Schmoll HJ; Bokemeyer C; Metzner B; Illiger HJ; Berdel W; Ostermann H; Manegold C; Räth U; Siegert W
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S198-202. PubMed ID: 1665492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.
    Blair SC; Zalupski MM; Baker LH
    Am J Clin Oncol; 1994 Dec; 17(6):480-4. PubMed ID: 7977164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ifosfamide combination regimens for soft-tissue sarcoma.
    Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
    Scinto AF; Ferraresi V; Milella M; Tucci E; Santomaggio C; Pasquali-Lasagni R; Del Vecchio MR; Campioni N; Nardi M; Cognetti F
    Br J Cancer; 1999 Nov; 81(6):1031-6. PubMed ID: 10576661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.
    Bokemeyer C; Schmoll HJ; Harstrick A; Illiger HJ; Metzner B; Räth U; Hohnloser J; Clemm C; Berdel W; Siegert W
    Eur J Cancer; 1993; 29A(16):2225-31. PubMed ID: 8110490
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
    Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M
    Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.
    Patel SR; Vadhan-Raj S; Burgess MA; Plager C; Papadopolous N; Jenkins J; Benjamin RS
    Am J Clin Oncol; 1998 Jun; 21(3):317-21. PubMed ID: 9626808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
    Leyvraz S; Perey L; Rosti G; Lange A; Pampallona S; Peters R; Humblet Y; Bosquée L; Pasini F; Marangolo M
    J Clin Oncol; 1999 Nov; 17(11):3531-9. PubMed ID: 10550151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
    J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
    Lopez AM; Ketchum M; Nichols H; Xu MJ; Peng YM; Dorr R; Alberts DS
    Cancer Chemother Pharmacol; 2000; 46(5):411-5. PubMed ID: 11127946
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E
    J Clin Oncol; 1993 Jan; 11(1):15-21. PubMed ID: 8418226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
    J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
    Trillet-Lenoir V; Soler P; Arpin D; Bohas C; Riou R; Court-Fortune I; Ecochard D; Perol M; Cordier JF
    Lung Cancer; 1996 Jun; 14(2-3):331-41. PubMed ID: 8794414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.